What GLP-1 is approved for weight loss?
Medically reviewed by: Dr. Alexandra Christiansen, MD
Written by: Levan Maglakelidze
Helimeds’ Fact-Checking Standards. Every piece of content at Helimeds adheres to the highest editorial standards for language, style, and medical accuracy. To learn what we do to deliver the best health insights to you, check out our content review principles.
Wegovy (semaglutide) is FDA-approved for weight loss and long-term weight management in eligible adults. Saxenda (liraglutide) is another GLP-1 medicine approved for weight management. Zepbound (tirzepatide) is also approved for weight management, although it acts on both GIP and GLP-1 receptors rather than GLP-1 alone.
The important distinction is the exact product, not just its active ingredient. Wegovy and Ozempic both contain semaglutide, but their approved uses are not identical. Likewise, Zepbound and Mounjaro both contain tirzepatide, but they have different indication lists.
FDA approval also does not mean a medicine is appropriate for everyone or covered by insurance. Understanding the product name, formulation, approved population, and safety limits helps you prepare for a useful prescribing conversation.
Which medicines have a weight-management indication?
GLP-1 stands for glucagon-like peptide-1, a hormone involved in appetite and blood sugar regulation. GLP-1 receptor agonists activate the receptors that respond to this hormone. They can reduce appetite and help people feel full, making it easier to eat less.
These medicines are used with nutrition and physical activity changes. They are prescription treatments for a chronic health condition, rather than products approved for anyone who wants to lose a few pounds.
The following comparison highlights established options and their important differences. It is not a substitute for checking the current label of a specific product, particularly when comparing newer brands or presentations.
| Product | Active ingredient | Receptor activity | Formulation distinction | Weight-management distinction |
|---|---|---|---|---|
| Wegovy | Semaglutide | GLP-1 | Injectable and oral formulations exist | Approved for eligible adults; pediatric indications depend on the formulation |
| Saxenda | Liraglutide | GLP-1 | Injection | A liraglutide product specifically approved for weight management |
| Zepbound | Tirzepatide | GIP and GLP-1 | Injection | Approved for weight management in eligible adults |
Wegovy: semaglutide with a weight-management indication
Wegovy is a semaglutide product approved to help adults with obesity, or adults with overweight and weight-related medical problems, lose weight and keep it off. Current Wegovy labeling includes both injectable and oral formulations. An older description that says Wegovy is available only as an injection is incomplete.
Helimeds' Wegovy treatment-information page describes its branded injectable treatment pathway.
Formulation matters beyond personal preference. An oral tablet and an injection have different administration instructions, and their approved populations are not necessarily identical. You should not apply instructions for one presentation to another.
Wegovy also has a cardiovascular-risk-reduction indication for certain adults with established cardiovascular disease and overweight or obesity. That is a separate approved use with its own population requirements. It does not mean everyone taking Wegovy receives the same cardiovascular benefit.
The Wegovy U.S. prescribing information is the appropriate reference for the exact formulation, approved use, and safety information. When discussing Wegovy versus Ozempic, start with the intended treatment goal rather than assuming that a shared ingredient makes the products interchangeable.
Saxenda: liraglutide for weight management
Saxenda is a GLP-1 receptor agonist containing liraglutide. It is a weight-management product, while Victoza is a different liraglutide product associated with diabetes treatment.
That distinction is useful when a prescription, insurance document, or pharmacy listing says only "liraglutide." The ingredient name does not tell you everything about the product's indication or instructions. Confirm the exact medication and its intended use.
Saxenda belongs in a conversation about approved GLP-1 weight-management options even when semaglutide or tirzepatide receives more attention. Whether it makes sense for an individual depends on medical history, tolerability, administration preferences, access, and the clinician's assessment. Familiarity or advertising visibility alone cannot settle that decision.
Zepbound: a related medicine with two receptor targets
Zepbound contains tirzepatide, which activates receptors for both GIP, or glucose-dependent insulinotropic polypeptide, and GLP-1. It is often grouped with GLP-1 medicines in everyday discussion, but "dual GIP/GLP-1 receptor agonist" is the more precise description.
Zepbound has an approved weight-management use for eligible adults with obesity, or overweight with a weight-related health condition. Mounjaro also contains tirzepatide, but a Mounjaro prescription is not the same product identity as a Zepbound prescription.
Helimeds provides separate Zepbound treatment information for its branded-medication pathway.
The Zepbound U.S. prescribing information provides the product-specific indication and warnings. Acting on two receptors does not, by itself, tell you how much weight a person will lose or establish that Zepbound is the right choice for them.
Why Ozempic and other diabetes brands cause confusion
A medicine can cause weight loss without being FDA-approved specifically for weight management. This explains much of the confusion surrounding GLP-1 brand names.
FDA approval applies to a particular product for particular uses and populations. It does not automatically extend to every preparation containing the same ingredient.
A shared ingredient does not mean shared approval
Wegovy and Ozempic contain semaglutide. Zepbound and Mounjaro contain tirzepatide. Saxenda and Victoza contain liraglutide.
Those ingredient pairings help explain the names, but they do not erase differences in approved indications, formulations, devices, strengths, or instructions. Ozempic and Mounjaro are diabetes-associated brands, not the brands carrying the weight-management indications discussed above. Their other approved uses should also be checked individually rather than reduced to a blanket statement that all diabetes brands have identical labels.
If you are considering semaglutide versus tirzepatide, separate two questions: which ingredient may suit your medical needs, and which exact product is being prescribed for which purpose?
FDA approval belongs to the specific product and indication. A shared active ingredient does not transfer approval to another brand or compounded preparation.
Off-label prescribing is a separate decision
A licensed clinician may prescribe an FDA-approved medicine for a use outside its approved labeling. This is called off-label prescribing.
Off-label use is not the same as an FDA-approved weight-management indication. It requires an individualized clinical judgment, and an insurer may apply different coverage rules. A prescription also does not mean the FDA has evaluated that specific off-label use.
If a clinician proposes a diabetes-branded medicine primarily for weight loss, reasonable questions include why that product is being considered, what evidence supports the choice, and how it compares with a product carrying a weight-management indication. Do not switch brands or combine treatments on your own.
Who may qualify for an approved weight-management medicine?
For adults, weight-management indications generally distinguish between obesity and overweight accompanied by a weight-related health condition. You do not necessarily need type 2 diabetes to be considered for an obesity medication.
Still, meeting a screening criterion is only the beginning of the assessment. A clinician needs to determine whether the likely benefits outweigh the risks for you.
Body size is one part of eligibility
Body mass index, or BMI, uses height and weight to estimate body size. Clinicians may use it when assessing whether a person fits a medication's labeled population, but BMI does not describe every aspect of health.
Conditions such as high blood pressure, abnormal cholesterol, and type 2 diabetes can be relevant to a weight-management assessment. The clinician should confirm which conditions you actually have rather than infer them from symptoms or a questionnaire score.
Bring recent height and weight measurements if available, along with relevant diagnoses and laboratory results. Accurate information is more useful than trying to make yourself fit an eligibility category. A numerical threshold never guarantees that a prescription will be appropriate.
Medical history can change the choice
Two people with similar BMI values may need different care plans. Previous medication reactions, digestive problems, kidney concerns, pregnancy plans, and other prescriptions can all affect the assessment.
A history of an eating disorder or difficulty maintaining adequate nutrition also deserves an honest discussion. Appetite reduction is not automatically helpful in every situation, and a sustainable plan must account for nutritional needs.
Medication may be one part of care alongside nutrition support, physical activity, behavioral treatment, or other obesity treatments. A clinician can also explain when a non-GLP-1 medicine or referral for another treatment approach deserves consideration. Declining or being unsuitable for a GLP-1 does not mean there are no useful next steps.
How to compare options without chasing a headline
Once you know which products have a relevant indication, the next question is which option fits your health needs and daily life. Approval establishes a treatment option; it does not rank that option as best for everyone.
Compare benefits in the population actually studied
These medicines can help eligible people reduce weight and maintain weight loss while treatment continues. Reducing appetite can make a nutrition plan more manageable, especially when hunger has made previous efforts difficult.
However, a percentage from a clinical trial is an average for a defined group receiving a particular medicine, formulation, and treatment protocol. It is not a prediction of your result. Studies can differ in whether participants had diabetes, how long they were followed, and how treatment interruptions were handled.
When reviewing Wegovy versus Zepbound, ask whether a comparison came from a direct head-to-head trial or separate studies. Also consider outcomes beyond the scale, including relevant health conditions, ability to eat adequately, and whether side effects allow continued treatment.
A result from a branded-drug trial is not evidence that a compounded preparation will produce the same outcome.
Consider administration, follow-up, and affordability
An oral option may appeal to someone who dislikes needles, while an injection may fit another person's routine better. Neither route is automatically simpler. The practical question is whether you can follow the exact product's instructions consistently.
Before choosing a treatment, clarify:
- Which brand and formulation would be prescribed, and why?
- What administration requirements could affect your daily routine?
- How will side effects, nutritional intake, and treatment response be assessed?
- What should you do if access is interrupted or you cannot tolerate treatment?
- What costs are recurring, and which services or supplies are included?
Insurance coverage, clinical eligibility, and pharmacy availability are separate issues. A plan may require prior authorization or exclude weight-management medication even when a clinician considers treatment appropriate.
Because obesity care may be long term, discuss the continuing cost rather than only the first payment. Also ask how the care plan would be reassessed if the medicine is ineffective, difficult to tolerate, or no longer affordable.
Why compounded GLP-1 products are a separate category
Compounded semaglutide and compounded tirzepatide are not FDA-approved medicines. The FDA does not review compounded drugs for safety, effectiveness, and quality before they are marketed.
This distinction matters even when a compounded preparation is prescribed by a licensed clinician and dispensed by a pharmacy. Those steps do not make it FDA-approved or establish equivalence to Wegovy or Zepbound.
Helimeds also describes its compounded tirzepatide treatment pathway separately from branded Zepbound.
Compounding does not create a generic equivalent
A compounded preparation should not be described as "generic Wegovy" or "generic Zepbound." An FDA-approved generic and a compounded drug follow different regulatory pathways.
There can be circumstances in which compounding serves a patient's medical needs. However, a lower price, an added vitamin, or a past shortage does not by itself establish that a particular preparation is appropriate or legally permissible. Current policy and individual circumstances matter.
The FDA's information on unapproved GLP-1 drugs explains important concerns. When comparing compounded versus branded medication, ask the prescriber what specific need the preparation addresses and what its limitations mean for your care.
Clear dispensing instructions are essential
If an injectable preparation requires measurement, confirm the exact concentration, prescribed amount, and device with the dispensing pharmacist.
Milligrams describe an amount of medicine. Milliliters describe a volume of liquid. Syringe units are markings on a device. They are not interchangeable quantities, and a conversion depends on the exact preparation and syringe.
Do not borrow a dosing chart from another patient or infer instructions from a vial's size. If the label and directions are unclear or inconsistent, resolve the discrepancy with the prescriber or pharmacist before injecting.
Safety questions to resolve before treatment
A weight-management indication does not remove the need for safety screening. The current label and medication guide for the exact product should guide the discussion, particularly when formulations differ.
Helimeds' important safety information explains platform responsibilities and compounded-medication qualifications; it does not replace the exact product's label.
Thyroid warnings and other reasons treatment may be unsuitable
Wegovy and Zepbound carry boxed warnings concerning thyroid C-cell tumors. These tumors occurred in animal studies; whether the medicines cause medullary thyroid carcinoma, or MTC, in humans is unknown.
The products are contraindicated in people with a personal or family history of MTC or multiple endocrine neoplasia syndrome type 2, known as MEN 2. This does not mean every thyroid condition rules out treatment. Tell the clinician the specific diagnosis rather than reporting only "thyroid problems."
A prior serious allergic reaction to the relevant medicine or its ingredients is another important contraindication. Review any history of pancreatitis, gallbladder problems, severe digestive symptoms, kidney disease, and diabetes-related eye disease. These conditions require product-specific assessment rather than an automatic assumption that treatment is safe or prohibited.
Common symptoms and warning signs need different responses
Nausea, vomiting, diarrhea, constipation, and abdominal discomfort can occur with these treatments. Their severity and effect on eating, drinking, and daily activity matter. Persistent symptoms deserve clinical attention rather than a promise that they will disappear by a particular deadline.
Helimeds' guide to tirzepatide side effects discusses common symptoms and serious risks for that ingredient.
Severe or persistent abdominal pain needs prompt assessment, especially with vomiting or pain extending toward the back. Wegovy's medication guidance instructs patients to stop using it and contact their healthcare provider right away for symptoms suggesting pancreatitis.
Other warning signs include upper abdominal pain with fever or jaundice, or ongoing vomiting and diarrhea that can cause dehydration and kidney problems. Low blood sugar risk is particularly important when treatment is combined with insulin or certain other diabetes medicines.
For trouble breathing, throat swelling, or another immediate medical emergency, call 911.
Common digestive side effects do not make severe pain, dehydration, or an allergic reaction a normal adjustment to push through.
Pregnancy, other medicines, and procedures require planning
Discuss pregnancy plans and breastfeeding before treatment. These considerations are product- and formulation-specific; an instruction for an injection should not automatically be applied to a tablet.
For Wegovy, patient information advises stopping treatment two months before a planned pregnancy. Arrange that plan with the treating clinician. Review contraception as part of the medication assessment as well, because interactions and precautions differ between products.
Give the clinician a complete medication list, including other weight-management or diabetes medicines. Do not combine GLP-1 treatments or add another product containing the same ingredient on your own.
Tell the anesthesia and procedure team if you use one of these medicines. Delayed stomach emptying can matter during anesthesia or deep sedation. The team should provide an individualized plan rather than relying on a universal medication-withholding rule.
Preparing for a prescribing conversation
Bring enough information for the clinician to assess both suitability and a workable care plan. Useful details include your current medicines, relevant diagnoses, previous weight-management treatments, allergies, and any digestive symptoms.
It also helps to state your priorities plainly. You may want to reduce a weight-related health risk, understand an oral option, avoid a previous side effect, or find a plan you can maintain financially. These priorities can guide the comparison without making a prescription inevitable.
If you choose an online assessment through Helimeds, the process begins with a medical intake. An affiliated licensed clinician reviews the information and may request additional details, testing, a call, or in-person evaluation. Treatment is prescribed only if clinically appropriate and permitted in your state; pharmacy dispensing and delivery are separate steps.
Helimeds lists branded Wegovy and Zepbound separately from compounded treatment pathways. That listing does not establish current stock, a particular presentation, or individual eligibility. Beginning a consultation is a request for assessment, not automatic approval.
Conclusion
Wegovy and Saxenda are GLP-1 products with weight-management indications. Zepbound is another approved weight-management option, with activity at both GIP and GLP-1 receptors. Diabetes-associated brands and compounded preparations should not be treated as interchangeable versions of those products.
Your next step is to confirm the exact medication, formulation, and intended indication with a licensed clinician, then discuss safety, follow-up, and ongoing access. If you begin a Helimeds intake, use it to provide an accurate health history and explore whether an offered treatment is appropriate after clinical review.
This article provides general health information and does not replace advice from your licensed healthcare professional.
Frequently asked questions
Do you need diabetes to qualify for a GLP-1 weight-management medicine?
No. Certain weight-management products are approved for eligible adults with obesity, or overweight with a weight-related health condition, whether or not they have diabetes. A clinician must still assess the exact product's criteria, your medical history, and safety considerations.
Is an oral GLP-1 automatically approved for weight loss?
No. Approval depends on the specific product and indication, not simply whether it is a pill. Wegovy has an oral formulation with a weight-management indication, but that does not make every oral GLP-1 product a weight-loss medicine.
Does FDA approval mean insurance will cover the medication?
No. FDA approval and insurance coverage are separate decisions. Your insurer may apply benefit exclusions, prior authorization requirements, or other conditions, so confirm coverage for the exact product and formulation.
Can a clinician switch you between semaglutide and tirzepatide?
A clinician may consider a switch based on response, side effects, medical needs, or access. These ingredients do not have a universal dose conversion, and their products have different instructions. Do not overlap, substitute, or change treatment without a specific prescribing plan.
History
Current Version
Written by Levan Maglakelidze
Medically reviewed by Dr. Alexandra Christiansen, MD






